Talphera (NASDAQ:TLPH) Earns Buy Rating from Analysts at Rodman & Renshaw

Analysts at Rodman & Renshaw started coverage on shares of Talphera (NASDAQ:TLPH) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Rodman & Renshaw’s price objective indicates a potential upside of 469.80% from the company’s previous close.

A number of other research firms have also recently commented on TLPH. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Talphera in a research report on Tuesday, January 21st. Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Performance

Shares of Talphera stock opened at $0.70 on Tuesday. Talphera has a fifty-two week low of $0.50 and a fifty-two week high of $1.61. The stock has a 50 day moving average of $0.65 and a 200 day moving average of $0.82. The firm has a market capitalization of $11.96 million, a price-to-earnings ratio of -1.02 and a beta of 0.28.

Institutional Trading of Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. purchased a new stake in Talphera, Inc. (NASDAQ:TLPH) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera makes up approximately 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera as of its most recent filing with the SEC. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.